Scholars Central

Conference abstractPublished 8 Jun 2018

AS-6 suppresses lipopolysaccharide–induced neuroinflammation in BV2 microglial cells via inhibition of NF-κB and MAPK pathway

Authors: Jun Young Park, Sun-Hyung Ha, Fukushi Abekura, Hak Seong Lim, Cheorl-Ho Kim

SungKyunKwan University, South Korea

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

4-O-carboxymethylascochlorin (AS-6, MW 462.96) isolated from Ascochyta viciae has been known to promote cell cycle arrest and inhibit invasion of tumor cells. We have previously studied structurally similar compounds ascochlorin (ASC; MW 404.93) and ascofuranone (AF; MW 420.93) with regard to its anti-inflammatory activity. In this study, we have found that the production of nitric oxide (NO), a main regulator of inflammation, is suppressed by AS-6 on BV2 microglial cells, when induced by LPS. In addition, AS-6 attenuated the increase in cyclooxyenase-2 (COX-2) protein and mRNA levels in lipopolysaccharide (LPS)-activated BV2 microglial cells in a dose-dependent manner. Moreover, AS-6 inhibited the expression and release of pro-inflammatory cytokines of tumor necrosis factor-alpha (TNF-Ã?±), interleukin-6 (IL-6), and interleukin-1Ã?² (IL-1Ã?²) in BV2 microglial cells. At the intracellular level, AS-6 inhibited LPS-induced nuclear translocation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-Ã?ºB) in BV2 microglial cells. Therefore, we investigated whether AS-6 affects mitogen-activated protein kinase (MAPK) phosphorylation, a process known as the upstream signaling regulator. AS-6 dramatically reduced the expression level of the phosphorylated forms of ERK, JNK, and p38 in LPS-activated BV2 microglial cells. These results indicate that AS-6 is a promising suppressor of the vascular inflammatory responses and AS-6 suppresses the LPS-induced inflammatory response in BV2 microglial cells by suppression of NFÃ?ºB and MAPKs signaling. Accordingly, AS-6 is suggested as a beneficial agent for the treatment of diseases that are associated with inflammation.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Jun Young Park”
  • BylineArticles whose byline prints “Sun-Hyung Ha”
  • BylineArticles whose byline prints “Fukushi Abekura”
  • BylineArticles whose byline prints “Hak Seong Lim”
  • BylineArticles whose byline prints “Cheorl-Ho Kim”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels